| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
|
Medicine details |
|
| Medicine name | encorafenib (Braftovi™) |
| Formulation | 50 mg, 70 mg capsule |
| Reference number | 3815 |
| Indication | In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation |
| Company | Pierre Fabre Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/07/2018 |
| NICE guidance | |